View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Liver/Biliary Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
November 05, 2022
1 min read
Save

Alcohol-related hepatitis soars during pandemic, particularly in women, young adults

Alcohol-related hepatitis soars during pandemic, particularly in women, young adults

WASHINGTON — The number of cases of alcohol-related hepatitis increased by more than 60% from 2019 to 2021 in three California hospitals, with women and young adults most affected, according to research presented at The Liver Meeting.

SPONSORED CONTENT
November 05, 2022
1 min read
Save

Low-resource neighborhoods linked to higher risk for pediatric NAFLD

Low-resource neighborhoods linked to higher risk for pediatric NAFLD

WASHINGTON — Children who reside in low-resource neighborhoods may be at increased risk for non-alcoholic fatty liver disease, according to study results presented at The Liver Meeting.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
November 03, 2022
1 min read
Save

FDA clears at-home screening tool to assess risk for lung, liver disease linked to alpha-1

FDA clears at-home screening tool to assess risk for lung, liver disease linked to alpha-1

Grifols announced that its at-home service to test for genetic risk related to alpha1-antitrypsin deficiency has received clearance from the FDA.

SPONSORED CONTENT
November 03, 2022
1 min read
Save

FDA expands Vemlidy approval for chronic HBV in children aged older than 12 years

FDA expands Vemlidy approval for chronic HBV in children aged older than 12 years

The FDA has updated the label indication for 25 mg tenofovir alafenamide for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 12 years older.

SPONSORED CONTENT
October 28, 2022
1 min read
Save

FDA rejects Gilead’s bulevirtide for hepatitis D, compensated liver disease

FDA rejects Gilead’s bulevirtide for hepatitis D, compensated liver disease

The FDA issued a complete response letter to Gilead indicating it cannot approve the company’s new drug application that seeks approval of bulevirtide for chronic hepatitis D virus infection and compensated liver disease.

SPONSORED CONTENT
October 26, 2022
1 min read
Save

Smoking, cirrhosis predictors of diabetes mellitus in patients with acute pancreatitis

Smoking, cirrhosis predictors of diabetes mellitus in patients with acute pancreatitis

CHARLOTTE, N.C. — Local injury, toxin exposure and systemic disease were among the top contributors to development of diabetes mellitus in patients with acute pancreatitis, according to a researcher at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
October 19, 2022
2 min read
Save

Shift in hepatitis A outbreaks ‘unprecedented’ in HAV vaccine era, CDC reports

Shift in hepatitis A outbreaks ‘unprecedented’ in HAV vaccine era, CDC reports

Recent and ongoing outbreaks associated with person-to-person transmission have marked a shift in hepatitis A virus epidemiology in the United States, according to data published in Morbidity and Mortality Weekly Report.

SPONSORED CONTENT
October 10, 2022
2 min read
Save

Terlipressin should be used with caution in hepatorenal syndrome type 1, grade 3 ACLF

Terlipressin should be used with caution in hepatorenal syndrome type 1, grade 3 ACLF

Patients with hepatorenal syndrome type 1 and advanced acute-on-chronic liver failure had significantly greater incidence of respiratory failure and 90-day mortality when treated with terlipressin vs. placebo, according to research.

SPONSORED CONTENT
October 08, 2022
1 min read
Save

Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis

Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis

Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release.

SPONSORED CONTENT
October 06, 2022
7 min watch
Save

VIDEO: Post-transplant recovery protocol shortens pediatric ICU stays, improves experience

VIDEO: Post-transplant recovery protocol shortens pediatric ICU stays, improves experience

In this Healio video, Andrew J. Costandi, MD, MMM, details the Enhanced Recovery After Liver Transplantation protocol at Children’s Hospital Los Angeles, which shortened post-transplant ICU stays from 7 to 3 days in pediatric patients.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails